Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $134 from $131 and keeps an Overweight rating on the shares. Comirnaty Q3 revenues were ahead of consensus, and the company noted that the COVID-19 franchise is performing in-line with expectations, the analyst tells investors in a research note. The firm added BioNTech has seen and continues to expect stable share andd pricing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $181 from $185 at Clear Street
- BioNTech reports Q3 EPS EUR (0.12) vs. EUR 0.81 last year
- BioNTech Reports Q3 2025 Financials and Raises Revenue Guidance
- BioNTech Reports Q3 2025 Financial Results with Revenue Growth Amid Operating Loss
- BioNTech Q3 EPS EUR (0.12) vs. EUR (0.81) last year